| Element List | Current Year | Previous Year | %Change | ||
|---|---|---|---|---|---|
| Sales/Revenue | 460.48 | 394 | 16.87 | ||
| Gross Profit (Loss) | 286.84 | 243.36 | 17.87 | ||
| Operational Profit (Loss) | 108.41 | 91.03 | 19.09 | ||
| Net Profit (Loss) Attributable to Shareholders of the Issuer | 97.01 | 79.85 | 21.49 | ||
| Total Comprehensive Income Attributable to Shareholders of the Issuer | 95.03 | 76.81 | 23.72 | ||
| Total Shareholders Equity (after Deducting Minority Equity) | 416.24 | 368.21 | 13.04 | ||
| Profit (Loss) per Share | 4.85 | 3.99 | |||
| All figures are in (Millions) Saudi Arabia, Riyals | |||||
| Element List | Amount | Percentage of the capital (%) | |
|---|---|---|---|
| Profit (Losses) Resulting From The Change In Investment Propertie’s Fair Value | - | - | |
| All figures are in (Millions) Saudi Arabia, Riyals | |||
| Element List | Explanation |
|---|---|
| The reason of the increase (decrease) in the sales/ revenues during the current year compared to the last year | Middle East Pharmaceutical Industries Company achieved a total revenue of SAR 460.48 million for the year, marking a 16.87% year-on-year increase. Revenue growth in 2025 was driven by strong execution in the Saudi private market, particularly through pharmacies and hospitals, supported by continued expansion in government tenders and export. The year reflects a positive shift toward optimized channel mix, disciplined execution, and focused portfolio management. - Private Market: revenues from private customers amounted to SAR 310 million (67% of total sales), posting a 15.56% year-on-year growth, supported by the execution of strategic agreements with major pharmacy chains and hospitals. - Institutional Market (Public Sector): SAR 93 million (20% of total sales) reflecting a 23.45% year-on-year growth, mainly driven by tender wins. - International Market (Export Sector): SAR 57 million (13% of total sales) reflecting 13.98% year-on-year growth as a result of strong growth in the international markets including Iraq, Libya and Oman. In terms of revenues generated from the key therapeutic areas, pain management posted a year-on year growth of +80%; cardiometabolic, +28%; respiratory, +16%; and dermatology, +12%, which contributed to the overall growth in revenue of the company for 2025. |
| The reason of the increase (decrease) in the net profit during the current year compared to the last year is | Net profit for the year increased by 21.49% compared to the previous year, reaching SAR 97.01 million, primarily driven by strong revenue growth of 16.87% coupled with an improved gross profit margin through product mix diversification and economies of scale because of higher capacity utilization. The increase in gross profit was partly offset by the increase in selling & distribution expenses; and general & administrative expenses largely due to the company’s continuous investment in commercial and brand building activities, talent acquisition and development, and other related expenses to support growth. Overall, the growth in the net profit was a result of improved gross margin and responsible spending. |
| Statement of the type of external auditor's report | Unmodified opinion |
| Comment mentioned in the external auditor’s report, mentioned in any of the following paragraphs (other matter, conservation, notice, disclaimer of opinion, or adverse opinion) | The consolidated financial statements of the Group for the year ended 31 December 2024 were audited by another auditor who expressed an unmodified opinion on those consolidated financial statements on 25 Ramadhan 1446H (corresponding to 25 March 2025). |
| Reclassification of Comparison Items | No. |
| Additional Information | None |
| Attached Documents | Attached Documents |
